Healthcare provider profile · identity verified

Ne Moe, M.D

Family Practice · RIVERSIDE, CA · NPI 1407038953

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	549	191
Amlodipine Besylate	Amlodipine Besylate	231	84
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	221	48
Lisinopril	Lisinopril	217	78
Levothyroxine Sodium	Levothyroxine Sodium	212	68
Losartan Potassium	Losartan Potassium	194	66
Albuterol Sulfate Hfa	Albuterol Sulfate	168	67
Omeprazole	Omeprazole	166	68
Prednisone	Prednisone	138	98
Trazodone Hcl	Trazodone Hcl	134	35
Atenolol	Atenolol	133	45
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	132	48
Rosuvastatin Calcium	Rosuvastatin Calcium	126	48
Metformin Hcl	Metformin Hcl	125	45
Metoprolol Tartrate	Metoprolol Tartrate	124	40
Furosemide	Furosemide	122	48
Gabapentin	Gabapentin	122	49
Simvastatin	Simvastatin	116	38
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	113	19
Glipizide	Glipizide	105	31
Hydrochlorothiazide	Hydrochlorothiazide	94	37
Pradaxa	Dabigatran Etexilate Mesylate	89	26
Meloxicam	Meloxicam	87	39
Terazosin Hcl	Terazosin Hcl	84	33
Metformin Hcl Er	Metformin Hcl	83	31
Finasteride	Finasteride	80	25
Potassium Chloride	Potassium Chloride	73	35
Alendronate Sodium	Alendronate Sodium	72	27
Pantoprazole Sodium	Pantoprazole Sodium	72	27
Acetaminophen-Codeine	Acetaminophen With Codeine	71	26
Tamsulosin Hcl	Tamsulosin Hcl	65	27
Ibuprofen	Ibuprofen	59	22
Mirtazapine	Mirtazapine	56	21
Montelukast Sodium	Montelukast Sodium	56	25
Jardiance	Empagliflozin	55	19
Allopurinol	Allopurinol	53	22
Hydralazine Hcl	Hydralazine Hcl	52	19
Ozempic	Semaglutide	52	12
Sertraline Hcl	Sertraline Hcl	52	16
Azelastine Hcl	Azelastine Hcl	51	32
Cephalexin	Cephalexin	51	40
Morphine Sulfate Er	Morphine Sulfate	51	suppressed
Alprazolam	Alprazolam	50	suppressed
Ondansetron Hcl	Ondansetron Hcl	50	20
Wixela Inhub	Fluticasone Propion/Salmeterol	45	23
Buspirone Hcl	Buspirone Hcl	38	11
Escitalopram Oxalate	Escitalopram Oxalate	37	16
Tramadol Hcl	Tramadol Hcl	37	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	35	13
Sumatriptan Succinate	Sumatriptan Succinate	35	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	34	24
Breyna	Budesonide/Formoterol Fumarate	33	13
Hydroxyzine Hcl	Hydroxyzine Hcl	31	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	30	12
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	30	14
Carvedilol	Carvedilol	29	13
Ciclopirox	Ciclopirox	28	14
Fenofibrate	Fenofibrate	28	11
Spironolactone	Spironolactone	28	suppressed
Trospium Chloride	Trospium Chloride	27	14
Azithromycin	Azithromycin	26	24
Propranolol Hcl	Propranolol Hcl	26	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	24	11
Fluoxetine Hcl	Fluoxetine Hcl	24	suppressed
Lactulose	Lactulose	24	12
Tizanidine Hcl	Tizanidine Hcl	24	suppressed
Fluticasone Propionate	Fluticasone Propionate	23	11
Lorazepam	Lorazepam	23	suppressed
Lovastatin	Lovastatin	23	suppressed
Pregabalin	Pregabalin	23	suppressed
Alvesco	Ciclesonide	22	13
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Naproxen	Naproxen	22	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	21	21
Humulin N	Insulin Nph Human Isophane	21	suppressed
Metronidazole	Metronidazole	21	12
Temazepam	Temazepam	21	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	21	suppressed
Humalog	Insulin Lispro	20	suppressed
Pravastatin Sodium	Pravastatin Sodium	20	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	19	17
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Naratriptan Hcl	Naratriptan Hcl	19	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	19	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Metoprolol Succinate	Metoprolol Succinate	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	17
Famotidine	Famotidine	17	suppressed
Rizatriptan	Rizatriptan Benzoate	17	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	17	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	17	suppressed
Colchicine	Colchicine	16	suppressed
Benazepril Hcl	Benazepril Hcl	15	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	15	suppressed
Etodolac	Etodolac	15	14
Ezetimibe	Ezetimibe	15	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Ondansetron Odt	Ondansetron	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Clobetasol Propionate	Clobetasol Propionate	14	suppressed
Eliquis	Apixaban	14	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	13	suppressed
Glipizide Er	Glipizide	13	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	13	suppressed
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Hydrocortisone	Hydrocortisone	12	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	12	suppressed
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	12	suppressed
Sucralfate	Sucralfate	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error